Irunin Tablets Vaginal 200mg N10
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Itraconazole
Release form
Pills
Composition
Itraconazole 200 mg. Auxiliary substances: lactose (milk sugar), potato starch, sodium lauryl sulfate, povidone (polyvinylpyrrolidone), talc, magnesium stearate.
Pharmacological effect
Antifungal broad-spectrum drug, a derivative of triazole. Violates the synthesis of ergosterol cell membrane of fungi.; Active against yeast Candida spp. (including Candida albicans, Candida glabrata, Candida krusei).
Pharmacokinetics
With intravaginal administration, a local effective concentration of itraconazole is created. Systemic absorption is minimal.
Indications
- dermatomycosis; - fungal keratitis; - onychomycosis caused by dermatophytes and / or yeast and mold fungi; - Systemic mycoses: systemic aspergillosis and candidiasis, cryptococcosis (including cryptococcal meningitis), histoplasmosis, sporotrichosis, paracoccidioidomycosis, blastomycosis and other systemic or tropical mycoses; - Candidomycosis with damage to the skin or mucous membranes, including vulvovaginal candidiasis; - deep visceral candidiasis; - pityriasis versicolor.
Contraindications
- Individual hypersensitivity to the drug or its constituent parts. - simultaneous administration of drugs metabodiziruyuschihsya involving CYP3A4 enzyme: terfenadine, astemizole, mizolastine, cisapride, dofetilide, quinidine, pimozide, ngibitory reductase MMC-CoA such as simvastatin and lovastatin, triazolam, and midazolam (see also section "Interactions. drugs "); With care: children's age, severe heart failure, liver diseases (including those accompanied by liver failure), chronic renal failure.
Use during pregnancy and lactation
The purpose of the drug is contraindicated in the first trimester of pregnancy. In the II and III trimesters of pregnancy, the use of the drug is possible only if the expected benefit to the woman outweighs the potential risk to the fetus. If necessary, the use of Irunin during lactation breastfeeding should be stopped.
Dosage and administration
Inside, after a meal.; Indication Dose Duration; Vulvovaginal candidiasis 200 mg 2 times a day; or 200 mg 1 time a day 1 day; 3 days; Tinehen sore lichen 200 mg 1 time a day 7 days; Dermatomycosis of smooth skin 200 mg 1 time per day; 100 mg 1 time per day for 7 days; 15 days; Fungal keratitis 200 mg 1 time per day for 21 days; Lesions of highly keratinized areas of the skin, such as the hands and feet,require additional treatment for 15 days at 100 mg per day.; Oral candidiasis 100 mg 1 time per day for 15 days; The oral bioavailability of itraconazole may be reduced in some immunocompromised patients, for example, in patients with neutropenia, AIDS patients or with transplanted organs. Therefore, it may be necessary to double the dose.; Onychomycosis; Pulse therapy (see table). ; One course of pulse therapy consists in taking 2 capsules of Irunin daily; twice a day (200 mg twice a day) for one week. ; For the treatment of fungal infections of the nail plate brushes two courses are recommended. For the treatment of fungal infections of the nail plate foot, three courses are recommended (see table). The interval between courses, during which you do not need to take the drug, is 3 weeks. ; Clinical results will become apparent after the end of treatment, as nails grow back.; Localization of onychomycosis 1st week. 2-yaned 3rd week 4th week 5th week 6th week 7th week 8th week 9th week; Defeat of the nail plate of the feet, with or without a lesion of the nail plate of the hands; 1st course of the Week, free from Irunin; 2nd course of the Week, free from taking Irunin; 3rd course; Damage to the nail plate brushes 1st course of the Week, free from taking Irunin; 2nd year; OR; Continuous treatment: two capsules per day (200 mg once a day) for 3 months. ; Irunin derivation; from the skin and nail tissue is slower than from plasma. Thus, optimal clinical and mycological effects are achieved 2-4 weeks after the end of treatment for skin diseases and 6-9 months after the end of treatment of nail diseases. Systemic mycoses (recommended dosages vary depending on the type of infection); Indication Dose Average duration Remarks; Aspergillosis 200 mg 1 time per day 2-5 months Increase the dose to 200 mg 2 times a day in case of an invasive or disseminated disease; Candidiasis 100-200 mg 1 time per day from 3 weeks to 7 months; Cryptococcosis; e meningitis 200 mg 1 time per day from 2 months to 1 year Maintenance therapy (cases of meningitis) 200 mg 1 time per day; Cryptococcal; meningitis 200 mg twice a day; Histoplasmosis from 200 mg 1 time per day to 200 mg twice a day for 8 months; Sporotrichosis 100 mg 1 time a day for 3 months; Paracoccidioidomycosis 100 mg once a day for 6 months; Chromomycosis 100-200 mg once a day for 6 months; Blastomycosis from 100 mg once a day for up to 200 mg twice a day for 6 months
Side effects
On the part of the gastrointestinal tract: dyspepsia, nausea, abdominal pain and constipation, reversible increase in liver enzymes, cholestatic jaundice, hepatitis, anorexia. In very rare cases when applying Irunin; severe toxic liver damage developed, including the case of a fatal acute liver failure; ; From the side of the central nervous system: headache, fatigue, dizziness, peripheral neuropathy; From the side of the cardiovascular system: congestive heart failure and pulmonary edema; ; Other organs and systems: irregularities, menstrual cycle, allergic reactions (such as itching, rash, urticaria and angioedema), Stevens-Johnson syndrome, alopecia, hypokalemia, edema, dark urine staining, hypercreatininemia.
Overdose
The use of the drug in high doses does not cause any reactions and conditions that are life-threatening.; In case of accidental ingestion of the drug, gastric lavage should be carried out and oral activated charcoal should be administered orally. There is no specific antidote.
Interaction with other drugs
Drug interactions drug Irunin so far not installed.
special instructions
To prevent reinfection, simultaneous treatment of sexual partners is necessary, and hygiene rules should be observed. During treatment, it is recommended to refrain from sexual contact.; If clinical signs of infection persist after completion of treatment, a microbiological examination should be repeated to confirm the diagnosis.; If an allergic reaction occurs treatment should be discontinued. If necessary, the drug can be removed by flushing the vagina with boiled water.; Influencing the ability to drive vehicles and control mechanisms; The drug does not affect the ability to drive a car and activities associated with the need for high concentration of attention and speed of psychomotor reactions.